Charu Aggarwal

Charu Aggarwal is a clinical investigator and lung cancer specialist at the University of Pennsylvania with expertise in biomarker-driven treatment strategies for EGFR-mutant NSCLC. Her research focuses on combination regimens to overcome acquired resistance, including amivantamab plus chemotherapy after osimertinib failure and strategies targeting co-occurring MET amplification. She leads multiple early-phase trials and has contributed to consensus guidelines on EGFR testing and re-biopsy at progression. She is an active mentor and educator in thoracic oncology.